NAVLIN Daily NewsCheckout Today’s News
U.S. states are beginning to develop their own vaccination guidelines following growing upheaval and inconsistent policy at the federal levelSpecifically, Republican states like Florida are rolling back or eliminating vaccine mandates, while several Democrat-led states are breaking with the U.S. Centers for Disease Control and Prevention (CDC) and publishing their own, evidence-based immunization recommendationsThe trend offers a glimpse at an emerging policy rift where access to vaccines may depend on a state’s political affiliation
EVERSANA and Waltz Health announced a merger deal intended to shake up the traditional U.S. prescription drug access model by cutting through the industry’s "misaligned incentives and fragmented patient experiences"The pharmaceutical industry and UK government failed to reach an agreement on changes to the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG)Eli Lilly suspended shipments of Mounjaro (tirzepatide) to the UK ahead of the price hike set to come into effect starting next month
During a recent Cabinet meeting, President Trump and his officials emphasized that they are leveraging tariffs to achieve Most Favored Nation (MFN) drug pricing with major pharmaceutical companiesU.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. noted that the administration is “deep into MFN negotiations” with 14 companies, while President Trump claimed that "equalization" is coming "pretty soon"These comments cast doubt on the recent joint statement published by the White House and the European Union, which seemed to confirm that the U.S. and Europe have agreed to cap tariffs on pharmaceutical products at a 15% rate. The meeting also failed to answer several lingering questions regarding the implementation of MFN, including the scope of the pricing scheme and specifics around the so-called “price targets” that were supposed to be communicated to pharmaceutical manufacturers within 30 days of the executive order
A "Mounjaro rebate scheme" will be introduced for UK pharmacies offering private weight management services, following substantial price increases starting next monthCommunity Pharmacy England has reached an agreement with the Department of Health and Social Care (DHSC) so that reimbursement of NHS prescriptions (branded and generically written) for Mounjaro (tirzepatide) dispensed from September will be reimbursed at the increased UK list pricesAs of September 1, Mounjaro will cost between £133 and £330 per injection pen, depending on dosage in the UK. One pen contains four doses. Currently, it costs between £92 and £122
In a new interview published by pharmaphorum, Dr Pamela Vo, VP of HEOR and Value & Evidence at EVERSANA, shared her expert perspective on the EU’s Joint Clinical Assessment (JCA) and what it means for pharmaceutical companiesDr Vo emphasized that early planning is no longer optional – it is essential to market access success. “For market access and reimbursement in Europe, you need to demonstrate that your product is cost-effective or has an additional benefit beyond what's currently available,” she explained. “With the new EU HTA regulation, the importance of evidence-based assessments has been elevated.”EVERSANA has comprehensive capabilities in supporting JCA submissions. From joint scientific consultation (JSC) advice and evidence generation planning to strategy development and dossier writing, the company offers end-to-end support tailored to the new EU HTA framework. Dr Vo added: “We’re one of the first companies actively supporting clients through the JCA process [and] our hands-on experience positions us to guide companies through pre-JCA, during JCA, and post-JCA phases.”
EVERSANA and Waltz Health have announced a merger deal intended to shake up the traditional U.S. prescription drug access model by cutting through the industry’s "misaligned incentives and fragmented patient experiences"Specifically, EVERSANA will acquire Waltz in a deal that will integrate Waltz’s software-powered drug-price marketplaces and direct-to-payer model into EVERSANA’s global commercialization services, combining EVERSANA’s existing relationships with drug manufacturers with Waltz’s technology and broad payer footprintWaltz Health Co-founder and CEO, Mark Thierer, will serve as the combined company’s new leader, while EVERSANA CEO Jim Lang will continue to serve as a board member
The pharmaceutical industry and UK government have failed to reach an agreement on changes to the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG)Wes Streeting this week gave the Association of the British Pharmaceutical Industry (ABPI) a “private ultimatum” to either accept the government’s offer or conclude without an agreement, the latter of which has now been confirmedIn a statement sharing the news, the ABPI argued that the controversial medicines payment scheme is undermining UK patient access to innovative medicines and the competitiveness of the UK life sciences industry
The U.S. and EU have reached a trade framework capping tariffs on pharmaceutical products imported into the U.S. at 15%The announcement comes from a joint statement released by the White House that clarifies key details from the trade deal reached between U.S. President Donald Trump and European Commission President Ursula von der Leyen in JulyCritically, the statement confirms that the U.S. will cap tariffs on pharmaceutical products imported from the EU at 15%, which comprises Section 232 tariffs and the administration’s so-called Most Favored Nation (MFN) tariff rate
Recently, both Johnson & Johnson (J&J) and the Pharmaceutical Research and Manufacturers of America (PhRMA) issued reports highlighting growing concerns around the lack of program oversight and integrity within the 340B Drug Pricing ProgramThe J&J data brief highlights the program's exponential growth and compiles several studies demonstrating that large hospital systems and pharmacy benefit managers (PBMs) are profiting from 340B while failing to pass along savings to patients and driving up costs for taxpayers and employers. Meanwhile, the PhRMA analysis found that drug costs for patients with commercial insurance and Medicare are nearly 200% higher at 340B hospitals than at non-340B hospitals The reports suggest that manufacturers are looking to 340B reform as a top policy goal for when U.S. lawmakers return from their August recess
China’s National Healthcare Security Administration (NHSA) announced that 310 drugs were shortlisted for potential inclusion on the 2025 National Reimbursement Drug List (NRDL) Eli Lilly has revealed that it plans to increase the list price of Mounjaro in the UK to address “pricing inconsistencies compared to other developed countries, including in Europe.” It will now cost between £133 and £330 per injection pen, depending on dosage, compared to £92 and £122 The European Commission has added two more medicines to the list of products undergoing Joint Clinical Assessment (JCA) under the EU Health Technology Assessment Regulation. The new additions are tarlatamab, a biologic for extensive-stage small cell lung cancer, and catequentinib, a chemical for synovial sarcoma or leiomyosarcoma
650+
+99%
<24
4,000+
24x7
99.5%
